Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates

Journal of Cell Biology

Volumn 153, Issue 1, 2001, Pages 25-34

  Chun, Wanjoo ^a   Lesort, Mathieu ^a   Tucholski, Janusz ^a   Ross, Christopher A ^b   Johnson, Gail V W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Huntington's disease; Inclusions; Isopeptide bond; Polar zipper; Polyglutamine

Indexed keywords

HUNTINGTIN; POLYGLUTAMINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ARTICLE; COVALENT BOND; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION;

ANIMALS; GTP-BINDING PROTEINS; HUMANS; MUTAGENESIS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RABBITS; TRANSGLUTAMINASES; TUMOR CELLS, CULTURED;

EID: 0035795406     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.153.1.25     Document Type: Article

References (48)

1. Localization of transglutaminase in hippocampal neurons: Implications for Alzheimer's disease
2. Polyglutamine domains are substrates of tissue transglutaminase: Does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?
3. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability
4. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture
5. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
6. Select alterations in protein kinases and phosphatases during apoptosis of differentiated PC12 cells
7. The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates
8. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity
9. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
10. Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation
11. Human genetic diseases due to codon reiteration: Relationship to an evolutionary mechanism
12. Transglutaminases: Multifunctional cross-linking enzymes that stabilize tissues
13. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
14. The influence of huntingtin protein size on nuclear localization and cellular toxicity
15. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease
16. Amyloid formation by mutant huntingtin: Threshold, progressivity and recruitment of normal polyglutamine proteins
17. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
18. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch
19. Staurosporine induces a neuronal phenotype in SH-SY5Y human neuroblastoma cells that resembles that induced by the phorbol ester 12-O-tetradecanoyl phorbol-13 acetate (TPA)
20. Transglutaminase action imitates Huntington's disease: Selective polymerization of Huntingtin containing expanded polyglutamine
21. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: Relevance to diseases of the nervous system
22. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei
23. Mutant huntingtin expression in clonal striatal cells: Dissociation on inclusion formation and neuronal survival by caspase inhibition
24. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
25. Tissue transglutaminase is increased in Huntington's disease brain
26. The early cellular pathology of Huntington's disease
27. Neurological abnormalities in a knock-in mouse model of Huntington's disease
28. DRPLA aggregation and transglutaminase, revisited
29. Transglutaminases
30. A cellular model that recapitulates major pathogenic steps of Huntington's disease
31. Redistribution and differential extraction of soluble proteins in permeabilized cultured cells. Implications for immunofluorescence microscopy
32. Transglutaminase and the neuronal cytoskeleton in Alzheimer's disease
33. Polyamines in human brain: Regional distribution and influence of aging
34. Human neuroblastoma cells in culture: A model for neuronal cell differentiation and function
35. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment
36. Polar zippers: Their role in human disease
37. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases
38. Neuronal cell differentiation of human neuroblastoma cells by retinoic acid plus herbimycin A
39. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
40. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization
41. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo
42. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin
43. Incorporation of glutamine repeats makes protein oligomerize: Implications for neurodegenerative diseases
44. Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells
45. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice
46. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
47. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
48. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP